42794-77-4

Usage

Uses

Used in Organic Synthesis:
4,4,6-trimethyl-1,4-dihydropyrimidin-2-amine is utilized as a precursor in organic synthesis for the development of various bioactive molecules and compounds. Its unique structure allows for the creation of a wide range of chemical entities with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4,4,6-trimethyl-1,4-dihydropyrimidin-2-amine is employed as a key intermediate in the synthesis of drugs. Its ability to form various bioactive molecules makes it a valuable component in drug discovery and development processes.
Used in Agricultural Applications:
4,4,6-trimethyl-1,4-dihydropyrimidin-2-amine may have potential uses in the agricultural sector, possibly as a component in the development of agrochemicals or as a building block for other compounds with applications in crop protection and enhancement.
Used in Material Science:
4,4,6-trimethyl-1,4-dihydropyrimidin-2-amine could also find applications in material science, where its unique structure and properties might contribute to the development of new materials with specific characteristics, such as improved stability or reactivity.
Further research and testing are necessary to fully understand the properties and potential uses of 4,4,6-trimethyl-1,4-dihydropyrimidin-2-amine, as its applications may extend beyond the current understanding.

Upstream product

• 141-79-7 4-methyl-pent-3-en-2-one 
• 50-01-1 guanidine hydrochloride 
• 113-00-8 guanidine nitrate 

Downstream Products

• 4628-47-1 4,4,6-trimethyl-1,4-dihydropyrimidine-2(3H)-one 

Relevant academic research and scientific papers

Development of inhibitors of heterotrimeric Gαi subunits

Heterotrimeric G-proteins are the immediate downstream effectors of G-protein coupled receptors (GPCRs). Endogenous protein guanine nucleotide dissociation inhibitors (GDIs) like AGS3/4 and RGS12/14 function through GPR/Goloco GDI domains. Extensive characterization of GPR domain peptides indicate they function as selective GDIs for Gαi by competing for the GPCR and Gβγ and preventing GDP release. We modified a GPR consensus peptide by testing FGF and TAT leader sequences to make the peptide cell permeable. FGF modification inhibited GDI activity while TAT preserved GDI activity. TAT-GPR suppresses G-protein coupling to the receptor and completely blocked α2-adrenoceptor (α2AR) mediated decreases in cAMP in HEK293 cells at 100 nM. We then sought to discover selective small molecule inhibitors for Gαi. Molecular docking was used to identify potential molecules that bind to and stabilize the Gαi-GDP complex by directly interacting with both Gαi and GDP. Gαi-GTP and Gαq- GDP were used as a computational counter screen and Gαq-GDP was used as a biological counter screen. Thirty-seven molecules were tested using nucleotide exchange. STD NMR assays with compound 0990, a quinazoline derivative, showed direct interaction with Gαi. Several compounds showed Gαi specific inhibition and were able to block α2AR mediated regulation of cAMP. In addition to being a pharmacologic tool, GDI inhibition of Gα subunits has the advantage of circumventing the upstream component of GPCR-related signaling in cases of overstimulation by agonists, mutations, polymorphisms, and expression-related defects often seen in disease.

CYCLIZATION OF GUANIDINES WITH α,β-UNSATURATED KETONES: IMPROVED SYNTHESIS OF 2-AMINODIHYDROPYRIMIDINE DERIVATIVES CONTAINING GUANIDINE MOIETY

3,4-Dihydro-2-amino pyrimidine derivatives 4a, 4b, 4c, 4d, 4e and 4f containing guanidine moiety were succesfully synthesized by cyclization of free N-monosubstituted guanidines with α,β-unsaturated ketones in tertiary butanol at 25 deg C.These products a